{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:19:35Z","timestamp":1792091975616,"version":"4.4.0"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["CA021765"],"award-info":[{"award-number":["CA021765"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["CA21765"],"award-info":[{"award-number":["CA21765"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012524","name":"American Lebanese Syrian Associated Charities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012524","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41375-026-02962-x","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T08:15:21Z","timestamp":1777277721000},"page":"1352-1363","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Blinatumomab in pediatric acute lymphoblastic leukemia: current and future use"],"prefix":"10.1038","volume":"40","author":[{"given":"Nawachai","family":"Lertvivatpong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0605-7342","authenticated-orcid":false,"given":"Hiroto","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"2962_CR1","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/S0140-6736(25)00864-5","volume":"406","author":"H Kantarjian","year":"2025","unstructured":"Kantarjian H, Pui CH, Jabbour E. Acute lymphocytic leukaemia. Lancet. 2025;406:950\u201362.","journal-title":"Lancet"},{"key":"2962_CR2","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","volume":"105","author":"H Inaba","year":"2020","unstructured":"Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105:2524\u201339.","journal-title":"Haematologica"},{"key":"2962_CR3","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.3390\/jcm10091926","volume":"10","author":"H Inaba","year":"2021","unstructured":"Inaba H, Pui CH. Advances in the diagnosis and treatment of pediatric acute lymphoblastic leukemia. J Clin Med. 2021;10:1926.","journal-title":"J Clin Med"},{"key":"2962_CR4","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1200\/JCO.20.00494","volume":"39","author":"AL Angiolillo","year":"2021","unstructured":"Angiolillo AL, Schore RJ, Kairalla JA, Devidas M, Rabin KR, Zweidler-McKay P, et al. Excellent outcomes with reduced frequency of vincristine and dexamethasone pulses in standard-risk B-lymphoblastic leukemia: results from Children\u2019s Oncology Group AALL0932. J Clin Oncol. 2021;39:1437\u201347.","journal-title":"J Clin Oncol"},{"key":"2962_CR5","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1200\/JCO.22.02705","volume":"41","author":"R Pieters","year":"2023","unstructured":"Pieters R, de Groot-Kruseman H, Fiocco M, Verwer F, Van Overveld M, Sonneveld E, et al. Improved outcome for ALL by prolonging therapy for IKZF1 deletion and decreasing therapy for other risk groups. J Clin Oncol. 2023;41:4130\u201342.","journal-title":"J Clin Oncol"},{"key":"2962_CR6","doi-asserted-by":"publisher","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","volume":"119","author":"M Klinger","year":"2012","unstructured":"Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell\u2013engaging CD19\/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012;119:6226\u201333.","journal-title":"Blood"},{"key":"2962_CR7","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1126\/science.1158545","volume":"321","author":"R Bargou","year":"2008","unstructured":"Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321:974\u20137.","journal-title":"Science"},{"key":"2962_CR8","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","volume":"32","author":"MS Topp","year":"2014","unstructured":"Topp MS, G\u00f6kbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32:4134\u201340.","journal-title":"J Clin Oncol"},{"key":"2962_CR9","unstructured":"Amgen Inc. BLINCYTO\u00ae (blinatumomab) for injection, for intravenous use. Prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125557s029lbl.pdf. Accessed on March 14, 2026."},{"key":"2962_CR10","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","volume":"29","author":"MS Topp","year":"2011","unstructured":"Topp MS, Kufer P, G\u00f6kbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29:2493\u20138.","journal-title":"J Clin Oncol"},{"key":"2962_CR11","doi-asserted-by":"publisher","first-page":"5185","DOI":"10.1182\/blood-2012-07-441030","volume":"120","author":"MS Topp","year":"2012","unstructured":"Topp MS, G\u00f6kbuget N, Zugmaier G, Degenhard E, Goebeler ME, Klinger M, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012;120:5185\u20137.","journal-title":"Blood"},{"key":"2962_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","volume":"16","author":"MS Topp","year":"2015","unstructured":"Topp MS, G\u00f6kbuget N, Stein AS, Zugmaier G, O\u2019Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16:57\u201366.","journal-title":"Lancet Oncol"},{"key":"2962_CR13","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","volume":"21","author":"D Przepiorka","year":"2015","unstructured":"Przepiorka D, Ko CW, Deisseroth A, Yancey CL, Candau-Chacon R, Chiu HJ, et al. FDA approval: blinatumomab. Clin Cancer Res. 2015;21:4035\u20139.","journal-title":"Clin Cancer Res"},{"key":"2962_CR14","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836\u201347.","journal-title":"N Engl J Med"},{"key":"2962_CR15","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","volume":"35","author":"G Martinelli","year":"2017","unstructured":"Martinelli G, Boissel N, Chevallier P, Ottmann O, G\u00f6kbuget N, Topp MS, et al. Complete hematologic and molecular response in adult patients with relapsed\/refractory Philadelphia chromosome\u2013positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol. 2017;35:1795\u2013802.","journal-title":"J Clin Oncol"},{"key":"2962_CR16","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1182\/blood.2025028576","volume":"145","author":"MR Litzow","year":"2025","unstructured":"Litzow MR. Blitzing ALL with blinatumomab. Blood. 2025;145:2400\u20132.","journal-title":"Blood"},{"key":"2962_CR17","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1634\/theoncologist.2018-0179","volume":"23","author":"ED Pulte","year":"2018","unstructured":"Pulte ED, Vallejo J, Przepiorka D, Nie L, Farrell AT, Goldberg KB, et al. FDA supplemental approval: blinatumomab for treatment of relapsed and refractory precursor B-cell acute lymphoblastic leukemia. Oncologist. 2018;23:1366\u201371.","journal-title":"Oncologist"},{"key":"2962_CR18","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N G\u00f6kbuget","year":"2018","unstructured":"G\u00f6kbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522\u201331.","journal-title":"Blood"},{"key":"2962_CR19","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1158\/1078-0432.CCR-18-2337","volume":"25","author":"EY Jen","year":"2019","unstructured":"Jen EY, Xu Q, Schetter A, Przepiorka D, Shen YL, Roscoe D, et al. FDA approval: blinatumomab for patients with B-cell precursor acute lymphoblastic leukemia in morphologic remission with minimal residual disease. Clin Cancer Res. 2019;25:473\u20137.","journal-title":"Clin Cancer Res"},{"key":"2962_CR20","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","volume":"34","author":"A von Stackelberg","year":"2016","unstructured":"von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, et al. Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016;34:4381\u20139.","journal-title":"J Clin Oncol"},{"key":"2962_CR21","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1001\/jama.2021.0669","volume":"325","author":"PA Brown","year":"2021","unstructured":"Brown PA, Ji L, Xu X, Devidas M, Hogan LE, Borowitz MJ, et al. Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325:833\u201342.","journal-title":"JAMA"},{"key":"2962_CR22","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2021.0987","volume":"325","author":"F Locatelli","year":"2021","unstructured":"Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T, et al. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325:843\u201354.","journal-title":"JAMA"},{"key":"2962_CR23","doi-asserted-by":"publisher","first-page":"4230","DOI":"10.1158\/1078-0432.CCR-25-1034","volume":"31","author":"CA Rabik","year":"2025","unstructured":"Rabik CA, Wang S, Chadda R, Przepiorka D, Vallejo J, Jiang X, et al. FDA approval summary: Blinatumomab for the treatment of B-cell precursor acute lymphoblastic leukemia in the consolidation phase of multiphase chemotherapy. Clin Cancer Res. 2025;31:4230\u20138.","journal-title":"Clin Cancer Res"},{"key":"2962_CR24","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1200\/JCO.22.02200","volume":"41","author":"LE Hogan","year":"2023","unstructured":"Hogan LE, Brown PA, Ji L, Xu X, Devidas M, Bhatla T, et al. Children\u2019s Oncology Group AALL1331: Phase III trial of blinatumomab in children, adolescents, and young adults with low-risk B-Cell ALL in first relapse. J Clin Oncol. 2023;41:4118\u201329.","journal-title":"J Clin Oncol"},{"key":"2962_CR25","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1016\/S0140-6736(10)62002-8","volume":"376","author":"C Parker","year":"2010","unstructured":"Parker C, Waters R, Leighton C, Hancock J, Sutton R, Moorman AV, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet. 2010;376:2009\u201317.","journal-title":"Lancet"},{"key":"2962_CR26","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1200\/JCO.2005.03.3373","volume":"24","author":"JC Barredo","year":"2006","unstructured":"Barredo JC, Devidas M, Lauer SJ, Billett A, Marymont M, Pullen J, et al. Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a Pediatric Oncology Group study. J Clin Oncol. 2006;24:3142\u20139.","journal-title":"J Clin Oncol"},{"key":"2962_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29256","volume":"68","author":"C Hastings","year":"2021","unstructured":"Hastings C, Chen Y, Devidas M, Ritchey AK, Winick NJ, Carroll WL, et al. Late isolated central nervous system relapse in childhood B-cell acute lymphoblastic leukemia treated with intensified systemic therapy and delayed reduced dose cranial radiation: a report from the Children\u2019s Oncology Group study AALL02P2. Pediatr Blood Cancer. 2021;68:e29256.","journal-title":"Pediatr Blood Cancer"},{"key":"2962_CR28","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.3324\/haematol.2023.283818","volume":"109","author":"KU Lyons","year":"2024","unstructured":"Lyons KU, Gore L. Bispecific T-cell engagers in childhood B-acute lymphoblastic leukemia. Haematologica. 2024;109:1668\u201376.","journal-title":"Haematologica"},{"key":"2962_CR29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1158\/0008-5472.CAN-19-1131","volume":"80","author":"M Klinger","year":"2020","unstructured":"Klinger M, Zugmaier G, Nagele V, Goebeler ME, Brandl C, Stelljes M, et al. Adhesion of T cells to endothelial cells facilitates blinatumomab-associated neurologic adverse events. Cancer Res. 2020;80:91\u2013101.","journal-title":"Cancer Res"},{"key":"2962_CR30","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/s41577-025-01175-0","volume":"25","author":"LCD Smyth","year":"2025","unstructured":"Smyth LCD, Kipnis J. Redefining CNS immune privilege. Nat Rev Immunol. 2025;25:766\u201375.","journal-title":"Nat Rev Immunol"},{"key":"2962_CR31","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","volume":"388","author":"IM van der Sluis","year":"2023","unstructured":"van der Sluis IM, de Lorenzo P, Kotecha RS, Attarbaschi A, Escherich G, Nysom K, et al. Blinatumomab added to chemotherapy in infant lymphoblastic leukemia. N Engl J Med. 2023;388:1572\u201381.","journal-title":"N Engl J Med"},{"key":"2962_CR32","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1200\/JCO-25-01806","volume":"44","author":"M Vieira Martins","year":"2026","unstructured":"Vieira Martins M, de Lorenzo P, Kotecha RS, Attarbaschi A, Escherich G, Nysom K, et al. Sustained benefit of blinatumomab in infants with KMT2A-rearranged ALL: long-term outcomes, toxicity, and pharmacokinetics. J Clin Oncol. 2026;44:370\u20134.","journal-title":"J Clin Oncol"},{"key":"2962_CR33","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2411680","volume":"392","author":"S Gupta","year":"2025","unstructured":"Gupta S, Rau RE, Kairalla JA, Rabin KR, Wang C, Angiolillo AL, et al. Blinatumomab in standard-risk B-Cell acute lymphoblastic leukemia in children. N Engl J Med. 2025;392:875\u201391.","journal-title":"N Engl J Med"},{"key":"2962_CR34","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa2312948","volume":"391","author":"MR Litzow","year":"2024","unstructured":"Litzow MR, Sun Z, Mattison RJ, Paietta EM, Roberts KG, Zhang Y, et al. Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults. N Engl J Med. 2024;391:320\u201333.","journal-title":"N Engl J Med"},{"key":"2962_CR35","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","volume":"383","author":"R Fo\u00e0","year":"2020","unstructured":"Fo\u00e0 R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo M-C, et al. Dasatinib\u2013blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020;383:1613\u201323.","journal-title":"N Engl J Med"},{"key":"2962_CR36","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1200\/JCO.23.01075","volume":"42","author":"R Fo\u00e0","year":"2023","unstructured":"Fo\u00e0 R, Bassan R, Elia L, Piciocchi A, Soddu S, Messina M, et al. Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL. J Clin Oncol. 2023;42:881\u20135.","journal-title":"J Clin Oncol"},{"key":"2962_CR37","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","volume":"10","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, et al. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2023;10:e24\u2013e34.","journal-title":"Lancet Haematol"},{"key":"2962_CR38","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1200\/JCO.24.00272","volume":"42","author":"H Kantarjian","year":"2024","unstructured":"Kantarjian H, Short NJ, Haddad FG, Jain N, Huang X, Montalban-Bravo G, et al. Results of the simultaneous combination of ponatinib and blinatumomab in Philadelphia chromosome-positive ALL. J Clin Oncol. 2024;42:4246\u201351.","journal-title":"J Clin Oncol"},{"key":"2962_CR39","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1002\/cncr.34667","volume":"129","author":"M Queudeville","year":"2023","unstructured":"Queudeville M, Stein AS, Locatelli F, Ebinger M, Handgretinger R, G\u00f6kbuget N, et al. Low leukemia burden improves blinatumomab efficacy in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia. Cancer. 2023;129:1384\u201393.","journal-title":"Cancer"},{"key":"2962_CR40","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1158\/2643-3230.BCD-21-0038","volume":"2","author":"EW Meermeier","year":"2021","unstructured":"Meermeier EW, Welsh SJ, Sharik ME, Du MT, Garbitt VM, Riggs DL, et al. Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. Blood Cancer Discov. 2021;2:354\u201369.","journal-title":"Blood Cancer Discov"},{"key":"2962_CR41","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1182\/blood.2022015956","volume":"140","author":"N Philipp","year":"2022","unstructured":"Philipp N, Kazerani M, Nicholls A, Vick B, Wulf J, Straub T, et al. T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Blood. 2022;140:1104\u201318.","journal-title":"Blood"},{"key":"2962_CR42","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/sj.leu.2402890","volume":"17","author":"A L\u00f6ffler","year":"2003","unstructured":"L\u00f6ffler A, Gruen M, Wuchter C, Schriever F, Kufer P, Dreier T, et al. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19\/anti-CD3 single-chain antibody construct. Leukemia. 2003;17:900\u20139.","journal-title":"Leukemia"},{"key":"2962_CR43","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8:1219\u201326.","journal-title":"Cancer Discov"},{"key":"2962_CR44","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","volume":"24","author":"EJ Orlando","year":"2018","unstructured":"Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24:1504\u20136.","journal-title":"Nat Med"},{"key":"2962_CR45","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1182\/blood.2020006287","volume":"137","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Aldoss I, Qu C, Crawford JC, Gu Z, Allen EK, et al. Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. Blood. 2021;137:471\u201384.","journal-title":"Blood"},{"key":"2962_CR46","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1182\/blood-2016-05-718395","volume":"129","author":"F Braig","year":"2017","unstructured":"Braig F, Brandt A, Goebeler M, Tony H-P, Kurze A-K, Nollau P, et al. Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood. 2017;129:100\u20134.","journal-title":"Blood"},{"key":"2962_CR47","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1182\/blood.2024026655","volume":"146","author":"SK Silbert","year":"2025","unstructured":"Silbert SK, Rankin AW, Hoang CN, Semchenkova A, Myers RM, Zerkalenkova E, et al. Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia. Blood. 2025;146:437\u201355.","journal-title":"Blood"},{"key":"2962_CR48","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41586-018-0436-0","volume":"562","author":"TB Alexander","year":"2018","unstructured":"Alexander TB, Gu Z, Iacobucci I, Dickerson K, Choi JK, Xu B, et al. The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature. 2018;562:373\u20139.","journal-title":"Nature"},{"key":"2962_CR49","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","volume":"127","author":"R Gardner","year":"2016","unstructured":"Gardner R, Wu D, Cherian S, Fang M, Hanafi LA, Finney O, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127:2406\u201310.","journal-title":"Blood"},{"key":"2962_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27265","volume":"65","author":"MJ Oberley","year":"2018","unstructured":"Oberley MJ, Gaynon PS, Bhojwani D, Pulsipher MA, Gardner RA, Hiemenz MC, et al. Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia. Pediatr Blood Cancer. 2018;65:e27265.","journal-title":"Pediatr Blood Cancer"},{"key":"2962_CR51","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1038\/leu.2017.41","volume":"31","author":"J Duell","year":"2017","unstructured":"Duell J, Dittrich M, Bedke T, Mueller T, Eisele F, Rosenwald A, et al. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia. 2017;31:2181\u201390.","journal-title":"Leukemia"},{"key":"2962_CR52","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1007\/s12185-020-03047-w","volume":"113","author":"T Kobayashi","year":"2021","unstructured":"Kobayashi T, Ubukawa K, Fujishima M, Takahashi N. Correlation between increased immune checkpoint molecule expression and refractoriness to blinatumomab evaluated by longitudinal T cell analysis. Int J Hematol. 2021;113:600\u20135.","journal-title":"Int J Hematol"},{"key":"2962_CR53","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41577-022-00738-9","volume":"22","author":"M Quastel","year":"2022","unstructured":"Quastel M, Dustin M. The CD58\u2013CD2 axis in cancer immune evasion. Nat Rev Immunol. 2022;22:409.","journal-title":"Nat Rev Immunol"},{"key":"2962_CR54","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add6403","volume":"8","author":"Y Li","year":"2022","unstructured":"Li Y, Moriyama T, Yoshimura S, Zhao X, Li Z, Yang X, et al. PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia. Sci Adv. 2022;8:eadd6403.","journal-title":"Sci Adv"},{"key":"2962_CR55","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1182\/hematology.2019000018","volume":"2019","author":"L Schultz","year":"2019","unstructured":"Schultz L, Gardner R. Mechanisms of and approaches to overcoming resistance to immunotherapy. Hematol Am Soc Hematol Educ Program. 2019;2019:226\u201332.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2962_CR56","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/s41375-018-0265-z","volume":"33","author":"D Bhojwani","year":"2019","unstructured":"Bhojwani D, Sposto R, Shah NN, Rodriguez V, Yuan C, Stetler-Stevenson M, et al. Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. Leukemia. 2019;33:884\u201392.","journal-title":"Leukemia"},{"key":"2962_CR57","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1200\/JCO.19.03279","volume":"38","author":"NN Shah","year":"2020","unstructured":"Shah NN, Highfill SL, Shalabi H, Yates B, Jin J, Wolters PL, et al. CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial. J Clin Oncol. 2020;38:1938\u201350.","journal-title":"J Clin Oncol"},{"key":"2962_CR58","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1182\/blood.2022015795","volume":"140","author":"H Shalabi","year":"2022","unstructured":"Shalabi H, Qin H, Su A, Yates B, Wolters PL, Steinberg SM, et al. CD19\/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR. Blood. 2022;140:451\u201363.","journal-title":"Blood"},{"key":"2962_CR59","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1200\/JCO.22.01214","volume":"41","author":"T Wang","year":"2022","unstructured":"Wang T, Tang Y, Cai J, Wan X, Hu S, Lu X, et al. Coadministration of CD19- and CD22-directed chimeric antigen receptor T-cell therapy in childhood B-cell acute lymphoblastic leukemia: a single-arm, multicenter, phase II Trial. J Clin Oncol. 2022;41:1670\u201383.","journal-title":"J Clin Oncol"},{"key":"2962_CR60","doi-asserted-by":"publisher","first-page":"e433","DOI":"10.1016\/S2352-3026(23)00073-X","volume":"10","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, et al. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol. 2023;10:e433\u2013e444.","journal-title":"Lancet Haematol"},{"key":"2962_CR61","unstructured":"https:\/\/www.clinicaltrials.gov\/study\/NCT06533748 SJALL23H: Combination antigen-directed induction therapy for newly diagnosed patients with B-cell precursor acute lymphoblastic leukemia and lymphomaAccessed on March 14, 2026."},{"key":"2962_CR62","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","volume":"615","author":"GC Issa","year":"2023","unstructured":"Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023;615:920\u20134.","journal-title":"Nature"},{"key":"2962_CR63","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/JCO.24.00826","volume":"43","author":"GC Issa","year":"2025","unstructured":"Issa GC, Aldoss I, Thirman MJ, DiPersio J, Arellano M, Blachly JS, et al. Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101). J Clin Oncol. 2025;43:75\u201384.","journal-title":"J Clin Oncol"},{"key":"2962_CR64","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1182\/blood-2023-191109","volume":"142","author":"JA Webster","year":"2023","unstructured":"Webster JA, Luskin MR, Rimando J, Blackford A, Zeidan AM, Sharon E, et al. Blinatumomab in combination with immune checkpoint inhibitors (ICIs) of PD-1 and CTLA-4 in adult patients with relapsed\/refractory (R\/R) CD19 positive B-cell acute lymphoblastic leukemia (ALL): results of a phase I study [abstract]. Blood. 2023;142:966.","journal-title":"Blood"},{"key":"2962_CR65","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188\u201395.","journal-title":"Blood"},{"key":"2962_CR66","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1182\/blood-2021-148967","volume":"138","author":"AM Li","year":"2021","unstructured":"Li AM, Rabin KR, Kairalla J, Wang C, Devidas M, Militano O, et al. Blinatumomab associated seizure risk in patients with Down syndrome and B-lymphoblastic leukemia: an interim report from Children\u2019s Oncology Group (COG) study AALL1731 [abstract]. Blood. 2021;138:2304.","journal-title":"Blood"},{"key":"2962_CR67","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1182\/hematology.2021000269","volume":"2021","author":"D Bhojwani","year":"2021","unstructured":"Bhojwani D, Bansal R, Wayne AS. Managing therapy-associated neurotoxicity in children with ALL. Hematology. 2021;2021:376\u201383.","journal-title":"Hematology"},{"key":"2962_CR68","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31779","volume":"72","author":"AH Long","year":"2025","unstructured":"Long AH, Aftandilian C, Barmettler S, Alexander S. Hypogammaglobulinemia in children receiving targeted immunotherapies for B lineage malignancies: practical guidance for assessment and management. Pediatr Blood Cancer. 2025;72:e31779.","journal-title":"Pediatr Blood Cancer"},{"key":"2962_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.64","volume":"4","author":"G Zugmaier","year":"2014","unstructured":"Zugmaier G, Topp MS, Alekar S, Viardot A, Horst HA, Neumann S, et al. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J. 2014;4:244.","journal-title":"Blood Cancer J"},{"key":"2962_CR70","first-page":"47","volume":"110","author":"KA Thus","year":"2025","unstructured":"Thus KA, de Groot-Kruseman HA, Winkler-Seinstra P, Fiocco M, Segers H, van den Bos C, et al. Immunoglobulin prophylaxis prevents hospital admissions for fever in pediatric acute lymphoblastic leukemia: results of a multicenter randomized trial. Haematologica. 2025;110:47\u201354.","journal-title":"Haematologica"},{"key":"2962_CR71","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","volume":"149","author":"IM Otani","year":"2022","unstructured":"Otani IM, Lehman HK, Jongco AM, Tsao LR, Azar AE, Tarrant TK, et al. Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a work group report of the AAAAI primary immunodeficiency and altered immune response committees. J Allergy Clin Immunol. 2022;149:1525\u201360.","journal-title":"J Allergy Clin Immunol"},{"key":"2962_CR72","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1093\/cid\/cit684","volume":"58","author":"LG Rubin","year":"2014","unstructured":"Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:e44\u2013e100.","journal-title":"Clin Infect Dis"},{"key":"2962_CR73","unstructured":"National Comprehensive Cancer Network. NCCN guidelines: pediatric acute lymphoblastic leukemia. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ped_all.pdf. Accessed on March 14, 2026"},{"key":"2962_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43758-2","volume":"14","author":"N Nouri","year":"2023","unstructured":"Nouri N, Cao RG, Bunsow E, Nehar-Belaid D, Marches R, Xu Z, et al. Young infants display heterogeneous serological responses and extensive but reversible transcriptional changes following initial immunizations. Nat Commun. 2023;14:7976.","journal-title":"Nat Commun"},{"key":"2962_CR75","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/infdis\/jiab345","volume":"225","author":"R Giacomelli Cao","year":"2022","unstructured":"Giacomelli Cao R, Christian L, Xu Z, Jaramillo L, Smith B, Karlsson EA, et al. Early changes in interferon gene expression and antibody responses following influenza vaccination in pregnant women. J Infect Dis. 2022;225:341\u201351.","journal-title":"J Infect Dis"},{"key":"2962_CR76","doi-asserted-by":"publisher","first-page":"e011200","DOI":"10.1136\/jitc-2024-011200","volume":"13","author":"X Liang","year":"2025","unstructured":"Liang X, Luo B, Lin B, Liu D, Guo J, Lu W, et al. Characteristics of second primary malignancies following bispecific antibodies therapy. J Immunother Cancer. 2025;13:e011200.","journal-title":"J Immunother Cancer"},{"key":"2962_CR77","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/jnci\/djs344","volume":"104","author":"HM Conklin","year":"2012","unstructured":"Conklin HM, Krull KR, Reddick WE, Pei D, Cheng C, Pui CH. Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia. J Natl Cancer Inst. 2012;104:1386\u201395.","journal-title":"J Natl Cancer Inst"},{"key":"2962_CR78","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1200\/JCO.22.00263","volume":"40","author":"LM Jacola","year":"2022","unstructured":"Jacola LM, Conklin HM, Krull KR, Pei D, Cheng C, Reddick WE, et al. The impact of intensified CNS-directed therapy on neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia treated without cranial irradiation. J Clin Oncol. 2022;40:4218\u201327.","journal-title":"J Clin Oncol"},{"key":"2962_CR79","first-page":"222","volume":"27","author":"R Chakraborty","year":"2021","unstructured":"Chakraborty R, Hill BT, Majeed A, Majhail NS. Late effects after chimeric antigen receptor T cell therapy for lymphoid malignancies. Transpl Cell Ther. 2021;27:222\u20139.","journal-title":"Transpl Cell Ther"},{"key":"2962_CR80","first-page":"228","volume":"31","author":"L Maillie","year":"2025","unstructured":"Maillie L, Nasta SD, Svoboda J, Barta SK, Chong EA, Garfall AL, et al. Prolonged neurologic symptoms following immune effector cell-associated neurotoxicity syndrome in patients with large B-cell lymphoma treated with chimeric antigen receptor-modified T cell therapy. Transpl Cell Ther. 2025;31:228\u201335.","journal-title":"Transpl Cell Ther"},{"key":"2962_CR81","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/pbc.25773","volume":"63","author":"MJ Bitsko","year":"2016","unstructured":"Bitsko MJ, Cohen D, Dillon R, Harvey J, Krull K, Klosky JL. Psychosocial late effects in pediatric cancer survivors: A report from the Children\u2019s Oncology Group. Pediatr Blood Cancer. 2016;63:337\u201343.","journal-title":"Pediatr Blood Cancer"},{"key":"2962_CR82","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1200\/JCO.2017.76.4696","volume":"36","author":"KR Krull","year":"2018","unstructured":"Krull KR, Hardy KK, Kahalley LS, Schuitema I, Kesler SR. Neurocognitive outcomes and interventions in long-term survivors of childhood cancer. J Clin Oncol. 2018;36:2181\u20139.","journal-title":"J Clin Oncol"},{"key":"2962_CR83","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1200\/JCO.23.01392","volume":"42","author":"A Hodder","year":"2023","unstructured":"Hodder A, Mishra AK, Enshaei A, Baird S, Bhuller K, Elbeshlawi I, et al. Blinatumomab for first-line treatment of children and young persons with B-ALL. J Clin Oncol. 2023;42:907\u201314.","journal-title":"J Clin Oncol"},{"key":"2962_CR84","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1182\/blood-2024-205461","volume":"144","author":"A Hodder","year":"2024","unstructured":"Hodder A, Mishra AK, Connor P, Cummins M, Cheng D, Gattens M, et al. Blinatumomab with de-escalated chemotherapy for infant KMT2A-rearranged B-cell acute lymphoblastic leukemia [abstract]. Blood. 2024;144:2816.","journal-title":"Blood"},{"key":"2962_CR85","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1182\/blood-2005-12-011809","volume":"108","author":"Y Matloub","year":"2006","unstructured":"Matloub Y, Lindemulder S, Gaynon PS, Sather H, La M, Broxson E, et al. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children\u2019s Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children\u2019s Oncology Group. Blood. 2006;108:1165\u201373.","journal-title":"Blood"},{"key":"2962_CR86","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.19.01692","volume":"37","author":"S Jeha","year":"2019","unstructured":"Jeha S, Pei D, Choi J, Cheng C, Sandlund JT, Coustan-Smith E, et al. Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude Total Therapy Study 16. J Clin Oncol. 2019;37:3377\u201391.","journal-title":"J Clin Oncol"},{"key":"2962_CR87","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/NCC.0000000000001309","volume":"47","author":"JS Withycombe","year":"2024","unstructured":"Withycombe JS, Kubaney HR, Okada M, Yun CS, Gupta S, Bloom C, et al. Delivery of care for pediatric patients receiving blinatumomab: a Children\u2019s Oncology Group study. Cancer Nurs. 2024;47:451\u20139.","journal-title":"Cancer Nurs"},{"key":"2962_CR88","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/ajh.27227","volume":"99","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Zugmaier G, Agrawal V, Mart\u00ednez-S\u00e1nchez P, Rif\u00f3n Roca JJ, Cassaday RD, et al. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia. Am J Hematol. 2024;99:586\u201395.","journal-title":"Am J Hematol"},{"key":"2962_CR89","doi-asserted-by":"publisher","first-page":"e529","DOI":"10.1016\/S2352-3026(25)00144-9","volume":"12","author":"E Jabbour","year":"2025","unstructured":"Jabbour E, Lussana F, Mart\u00ednez-S\u00e1nchez P, Torrent A, Rif\u00f3n JJ, Agrawal V, et al. Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1\/2 trial. Lancet Haematol. 2025;12:e529\u2013e541.","journal-title":"Lancet Haematol"},{"key":"2962_CR90","doi-asserted-by":"publisher","first-page":"5117","DOI":"10.1182\/blood-2025-5117","volume":"146","author":"E Jabbour","year":"2025","unstructured":"Jabbour E, Lussana F, Mart\u00ednez-S\u00e1nchez P, Torrent A, Rif\u00f3n JJ, Agrawal V, et al. Efficacy of single-agent subcutaneous blinatumomab in adults with relapsed\/refractory (R\/R) B-cell acute lymphoblastic leukemia (B-ALL): results from a phase 1\/2 dose expansion study with extended follow-up [abstract]. Blood. 2025;146:5117.","journal-title":"Blood"},{"key":"2962_CR91","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/S1470-2045(19)30273-6","volume":"20","author":"ZJ Ward","year":"2019","unstructured":"Ward ZJ, Yeh JM, Bhakta N, Frazier AL, Girardi F, Atun R. Global childhood cancer survival estimates and priority-setting: a simulation-based analysis. Lancet Oncol. 2019;20:972\u201383.","journal-title":"Lancet Oncol"},{"key":"2962_CR92","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1200\/JCO.20.00642","volume":"38","author":"MI Patel","year":"2020","unstructured":"Patel MI, Lopez AM, Blackstock W, Reeder-Hayes K, Moushey EA, Phillips J, et al. Cancer disparities and health equity: a policy statement from the American Society of Clinical Oncology. J Clin Oncol. 2020;38:3439\u201348.","journal-title":"J Clin Oncol"},{"key":"2962_CR93","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s43058-022-00310-5","volume":"3","author":"C Duffy","year":"2022","unstructured":"Duffy C, Santana V, Inaba H, Jeha S, Pauley J, Sniderman L, et al. Evaluating blinatumomab implementation in low- and middle-income countries: a study protocol. Implement Sci Commun. 2022;3:62.","journal-title":"Implement Sci Commun"},{"key":"2962_CR94","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/S1470-2045(25)00549-2","volume":"26","author":"T Burki","year":"2025","unstructured":"Burki T. WHO updates lists of essential medicines. Lancet Oncol. 2025;26:1282.","journal-title":"Lancet Oncol"},{"key":"2962_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102825","volume":"76","author":"RJ Chan","year":"2024","unstructured":"Chan RJ, Knowles R, Ashbury FD, Bowen J, Chan A, Chin M, et al. Supportive care 2030 movement: towards unifying ambitions for global excellence in supportive cancer care-an international Delphi study. EClinicalMedicine. 2024;76:102825.","journal-title":"EClinicalMedicine"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02962-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02962-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02962-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:00:59Z","timestamp":1782918059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02962-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":95,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2962"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02962-x","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Nawachai Lertvivatpong has no conflicts of interest relevant to the subject of this article. Hiroto Inaba participates in the advisory boards of Syndax and Jazz Pharmaceuticals.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}